Deltex E3 Ubiquitin Ligase 3L confers radioresistance in prostate cancer via Akt pathway

Junyi Xiang1, Bodong Lv2, Shufeng Fan1, Zhitian Zhang1, Hui Yang3*
1Department of Medical Imaging, 2Department of Urology Surgery, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province 310000, 3Department of Urology Surgery, Chonqing Central Hospital of Chongqing, Chongqing City 409000, China

*For correspondence: Email: HUYOKL87yh@163.com; Tel: +86-23-979245641

Sent for review: 3 April 2020 Revised accepted: 25 June 2020

Abstract

Purpose: To determine the effect of Deltex E3 Ubiquitin Ligase 3L (DTX3L) on the radioresistance of prostate cancer (PCa).

Methods: A PCa cell model of radioresistance was established via exposure of cancer cell lines to fractionated radiation. The MTT assay and western blotting were performed to evaluate the impact of DTX3L on cell survival and DNA damage repair. The molecular mechanism of action was evaluated by western blotting.

Results: DTX3L was elevated in PCa cell lines compared with normal primary prostate epithelial cells (p < 0.01). The survival of PCa cells exposed to radiation was promoted by overexpression of DTX3L, while knockdown of DTX3L abrogated the radioresistance. Moreover, overexpression of DTX3L decreased phosphorylation of histone H2AX (γH2AX) and increased Rad51 levels (p < 0.01). However, knockdown of DTX3L reversed the accumulation of γH2AX and Rad51. Phosphorylation of AKT was promoted by DTX3L overexpression, but was reduced by DTX3L knockdown (p < 0.01). Inhibition of AKT (protein kinase B) counteracted the promotion ability of DTX3L on the radioresistance of PCa cells via decreased cell survival ratio, and also inhibited DNA damage repair via accumulation of γ-H2AX and depletion of Rad51 (p < 0.01).

Conclusion: DTX3L increases the resistance of prostate cancer to radiotherapy and DNA damage repair in PCa via AKT pathway, indicating a potential therapeutic strategy to overcome radioresistance in PCa.

Keywords: DTX3L (Deltex E3 Ubiquitin Ligase 3L), DNA damage, Phosphorylation, Radioresistance, AKT, Protein kinase B, Prostate cancer

INTRODUCTION

Prostate cancer (PCa) is common in males, with an increasing number of cases being diagnosed in the past decade [1]. Traditional treatments, including surgical resection, endocrine therapy, chemotherapy, and radiation therapy (RT) are effective for PCa [2]. RT is one of the most commonly used therapies for localized PCa due to its noninvasive nature and low risk [2]. However, the recurrence of PCa accompanied with radioresistance of PCa cells makes PCa a
fatal disease with a high mortality rate [2]. Therefore, new therapeutic targets are needed to identify and improve the radiosensitivity of PCa.

DTX3L (Deltex E3 Ubiquitin Ligase 3L) is an E3 ligase, which is widely expressed in different tissues with higher expression in the thymus [3]. DTX3L can bind with B invasive lymphoma 1, which is important for DLCBL (diffuse large B-cell lymphoma) [4]. Previous studies have shown that DTX3L participates in tumor progression, including those in glioma [5] and PCa [6]. DTX3L inhibits the expression of interferon response factor-1 and regulates proliferation of PCa cells [6]. However, the functional role of DTX3L in radioresistance of PCa is still not fully known.

AKT (protein kinase B) has been implicated in the mediation of pathways involved in cell proliferation, survival, and metabolism [7]. Activation of AKT via its regulator, phosphoinositide 3-kinase (PI3K), has shown oncogenic ability in various tumors, such as the promotion of metastasis in PCa [7]. Inhibition of AKT has been widely used for the treatment of PCa [8], and PI3K/AKT activation could result in the development of resistance to chemotherapy [9] and radiotherapy [10]. In addition, DTX3L can regulate the PI3K/AKT pathway to promote metastasis of melanoma [11]. Therefore, AKT might be associated with DTX3L-mediated radioresistance in PCa.

Therefore, this study was conducted to determine the relationship between DTX3L and the radioresistance in PCa cells. Furthermore, the effect of DTX3L on the AKT pathway involved in the radioresistance of PCa was also evaluated. The results could facilitate the development of a potent therapeutic target to overcome radioresistance of PCa.

**EXPERIMENTAL**

**Cell culture**

PCa cell lines (PC3, DU145, and LNCaP) and HPE were cultured in RPMI 1640 medium (Life Technologies, Gaithersburg, MD, USA) with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) at 37 °C and 5% CO₂.

**Cell transfection and treatment**

Full-length DTX3L DNA was inserted into the vector pcDNA 4.1 (Invitrogen, Carlsbad, CA, USA). To silence DTX3L, two short hairpin RNAs (shRNAs; shDTX3L 1# and 2#) were synthesized by GenePharma (Suzhou, China). PC3 cells were transfected with pcDNA-DTX3L or the negative control (vector), and DU145 cells were transfected with shRNAs (20 nM) or the negative control (shNC) using Lipofectamine 2000 (Invitrogen).

The cells, after different transfections, were treated with or without 2.5 μM MK-2206 for 24 h. The cells were then treated with 0, 2, 4, 6, or 8 Gy ionizing radiation using a 60Co clinical unit for 1 h before the functional assays.

**Cell viability**

PC3 or DU145 cells (9 × 10⁴ cells/well) after ionizing radiation treatment were seeded and incubated for 24 h. Each well was incubated with 10 μL MTT solution (Dojindo, Tokyo, Japan) for 4 h, and then incubated with 100 μL dimethyl sulfoxide. Absorbance at 570 nm for each well was determined using a micro ELISA reader (Bio-Tek, Winooski, VT, USA).

**Western blotting**

Proteins were extracted from PC3 or DU145 cells and subjected to SDS-PAGE. The proteins were transferred to a polyvinylidene fluoride membrane, and the membrane was incubated with the following primary antibodies: anti-DTX3L (1:1,500; Abcam, Cambridge, UK); γ-H2AX and Rad51 (1:2,000, Abcam); Akt and p-Akt (1:2,500, Abcam); and β-actin (1:3,000, Abcam) after blocking in 5% bovine serum albumin. The membrane was then incubated with horseradish peroxidase-labeled secondary antibody (Sungene, Tianjin, China), and the immunoreactivities were determined using the Millipore ECL system (Millipore, Billerica, MA, USA).

**Statistical analysis**

Data are shown as the mean ± standard error of mean and were analyzed using Prism 6 software (GraphPad, San Diego, CA, USA). Statistical analyses were conducted using one-way analysis of variance. A value of *p < 0.05 or **p < 0.01 was considered statistically significant.

**RESULTS**

**DTX3L conferred radioresistance to PCa cells**

Western blotting showed higher expression of DTX3L in PCa cells (PC3, DU145, and LNCaP) than in HPE cells (Figure 1 A). PC3 cells with the lowest expression of DTX3L were transfected with pcDNA-DTX3L (Figure 1 B), and DU145 cells with the highest DTX3L expression were transfected with shRNAs targeting DTX3L.
Survival curves of PC3 or DU145 cells after radiation were then evaluated. The results indicated that PC3 cells overexpressing DTX3L showed higher survival than the negative control (Figure 1C). However, DU145 cells with silenced DTX3L showed lower survival than the negative control (Figure 1C), demonstrating that DTX3L conferred radioresistance in PCa cells.

DTX3L promoted DNA damage repair in radioresistant PCa cells

Overexpression of DTX3L resulted in decreased γH2AX and increased Rad51 levels (Figure 2A), thus promoting DNA damage repair to enhance survival in radioresistant PCa cells. However, knockdown of DTX3L increased the protein expression levels of γH2AX, while it decreased Rad51 expression to enhance DNA damage in radioresistant PCa cells (Figure 2B).

DTX3L promoted AKT activation in radioresistant PCa cells

Data from western blotting showed that DTX3L increased phosphorylation of AKT in PC3 cells after treatment with 4 Gy radiation (Figure 3A), while knockdown of DTX3L decreased phosphorylation of AKT in DU145 cells (Figure 3B), suggesting that DTX3L promoted AKT activation in radioresistant PCa cells.
Inhibition of AKT attenuated DTX3L-induced radioresistance in PCa cells.

Inhibition of AKT via MK-2206 treatment decreased the viability of radioresistant PC3 cells (Figure 4 A), while overexpression of DTX3L increased the viability of radioresistant PC3 cells after MK-2206 treatment (Figure 4 A). Moreover, DNA damage repair was suppressed by MK-2206 treatment in radioresistant PC3 cells with increased γH2AX and decreased Rad51 levels (Figure 4 B and C). However, overexpression of DTX3L attenuated the MK-2206-induced increase of γH2AX and decrease of Rad51 levels (Figure 4 B and C). Furthermore, DTX3L overexpression reversed the suppressive effect of MK-2206 on AKT phosphorylation in radioresistant PC3 cells (Figure 4 B and C), suggesting that the inhibition of AKT attenuated DTX3L-induced radioresistance in PCa cells.

**Figure 4:** Inhibition of AKT attenuated DTX3L-induced radioresistance in PCa cells. (A) The effect of DTX3L and MK-2206 on the viability of PC3 cells after radiation. (B) The effect of DTX3L and MK-2206 on protein expression levels of γH2AX, Rad51, p-Akt, and Akt. (C) The relative γH2AX, Rad51 p-Akt, and Akt levels affected by DTX3L and MK-2206. *DTX3L vs. control or MK-2206; p < 0.05, p < 0.01; #, **DTX3L + MK-2206 vs. MK-2206, p < 0.05, p < 0.01

**DISCUSSION**

Previous research has shown that hyper-activation of the PI3K/AKT pathway is implicated in the radioresistance of PCa [19]. Activation of AKT could increase phosphorylation of downstream targets involved in cell survival, cell cycle, cell apoptosis, and tumor heterogeneity to promote the development of radioresistance in PCa [20]. Moreover, epithelial plasticity, including the epithelial-mesenchymal transition, has also been regarded as a critical driver of radioresistance in PCa [20]. The present study also confirmed that DTX3L promoted the activation of the AKT pathway via phosphorylation of Akt. However, the functional roles of DTX3L on the cell cycle, apoptosis, and the epithelial-mesenchymal transition in radioresistant PCa cells remain elusive. Furthermore, previous studies showed that DTX3L functioned as an activator of signal transduction and transcription signaling (STAT) in the regulation of chemoresistance and survival in PCa cells [6]. In addition, activation of STAT resulted in the dimerization of STAT and its translocation to the nucleus to bind with the promoter region of Akt [21]. Therefore, DTX3L might confer radioresistance in PCa via AKT-STAT pathway.
Inhibitors of the AKT pathway could be effective for increasing radiosensitivity of PCa [22]. For example, palomid 529 increased radiosensitivity in PC-3 cells in combination with radiation therapy [23]. Arsenic trioxide, an Akt inhibitor, could enhance radiosensitivity in LNCaP and PC-3 cells [24]. In the present study, consistent with the results of Thang et al [11], knockdown of DTX3L decreased phosphorylation of Akt. In addition, inhibition of AKT via MK-2206 attenuated DTX3L-induced radioresistance in PCa cells. Furthermore, various resistance pathways, including adaptive, DNA damage repair, inflammation, and hypoxic pathways are involved in the resistance against radiotherapy [25]. However, whether DTX3L regulates other resistance pathways during radioresistance in PCa needs to be investigated.

CONCLUSION

The findings of this study show that DTX3L confers radioresistance on PCa cells via regulation of Akt pathway. Thus, DTX3L might, therefore, be a potential therapeutic target for the improvement of radioresistance in PCa.

DECLARATIONS

Conflict of interest

No conflict of interest is associated with this work.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapostopenaccessinitiative.org/ready), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Li C-L, Han X-C, Zhang H, Wu J-S, Li B. Effect of scopoletin on apoptosis and cell cycle arrest in human prostate cancer cells in vitro. Trop J Pharm Res 2015; 14(4): 611-617.
2. Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA 2017; 317(24): 2532-2542.
3. Hakme A, Huber A, Dolle P, Schreiber V. The macroPARP genes Parp-9 and Parp-14 are developmentally and differentially regulated in mouse tissues. Dev Dyn 2008; 237(1): 209-215.
4. Takeyama K, Aguiar RC, Gu L, He C, Freeman GJ, Kutok JL, Aster JC, Shipp MA. The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. J Biol Chem 2003; 278(24): 21930-21937.
5. Xu P, Tao X, Zhao C, Huang Q, Chang H, Ban N, Bei Y, Xia X, Shen C, Wang K et al. DTX3L is upregulated in glioma and is associated with glioma progression. Int J Mol Med 2017; 40(2): 491-498.
6. Bachmann SB, Frommel SC, Camicia R, Winkler HC, Santoro R, Hassa PO. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Mol Cancer 2014; 13(125).
7. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007; 121(7): 1424-1432.
8. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009; 9(2): 237-249.
9. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002; 5(6): 234-248.
10. Chang L, Ni J, Beretov J, Wasinger VC, Hao J, Bucci J, Malouf D, Gillatt D, Graham PH, Li Y. Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach. Sci Rep 2017; 7(4834).
11. Thang ND, Yajima I, Kumasaka MY, Iida M, Suzuki T, Kato M. Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway. Oncotarget 2015; 6(16): 14290-14299.
12. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-386.
13. Juszczynski P, Kutok J, Li C, Mitra J, Aguilar TDF, Shipp M. BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate. Molecular and cellular biology 2006; 26(5348-5359).
14. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation
of the DNA damage response. Nature 2006; 444(7120): 756-760.

15. Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP, Shipp MA. BBAP Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response. Molecular Cell 2009; 36(1): 110-120.

16. Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis J, Shipp MA. BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8. Molecular Cellular Biol 2013; 33(4): 845-857.

17. Yang C-S, Jividen K, Spencer A, Dworak N, Ni L, Oostdyk LT, Chatterjee M, Kusmider B, Reon B, Parlak M et al. Ubiquitin Modification by the E3 Ligase/ADP-Ribosyltransferase Dtx3L/Parp9. Molecular Cell 2017; 66(4): 503-516.e505.

18. Willis N, Panday A, Duffey E, Scully R. Rad51 recruitment and exclusion of non-homologous end joining during homologous recombination at a Tus/Ter mammalian replication fork barrier. PLOS Genetics 2018; 14:e1007486.

19. Chang L, Graham PH, Hao J, Bucci J, Cozzi PJ, Kearsley JH, Li Y. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev 2014; 33(2-3): 469-496.

20. Park S, Kim YS, Kim DY, So I, Jeon J-H. PI3K pathway in prostate cancer: All resistant roads lead to PI3K.

21. Zegeye MM, Lindkvist M, Fälker K, Kumawat AK, Paramel G, Grenégard M, Sirsjö A, Ljungberg LU. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell communication and signaling: CCS 2018; 16(1): 55-55.

22. Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ, Li Y. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Critical Reviews in Oncol/Hematol 2015; 96(3): 507-517.

23. Diaz R, Nguewa PA, Diaz-Gonzalez JA, Hamel E, Gonzalez-Moreno O, Catena R, Serrano D, Redrado M, Sherris D, Calvo A. The novel Akt inhibitor Palomid 529 (PS529) enhances the effect of radiotherapy in prostate cancer. British J Cancer 2009; 100(6): 932-940.

24. Chiu H-W, Chen Y-A, Ho S-Y, Wang Y-J. Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells. PloS one 2012; 7(2): e31579-e31579.

25. Kim B, Hong Y, Lee S, Liu P, Lim J, Lee Y, Lee T, Chang K, Hong Y. Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. Int J Mol Sci 2015; 16(11): 26880-26913.